These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 12791810

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
    Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, Tafani M, Bezard E, Esquerré JP, Baulieu JL.
    J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.
    Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, Duda JE, Stern MB, Mozley D, Katz IR.
    J Nucl Med; 2005 Feb; 46(2):227-32. PubMed ID: 15695780
    [Abstract] [Full Text] [Related]

  • 25. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T.
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [Abstract] [Full Text] [Related]

  • 26. [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites.
    Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK.
    Synapse; 2001 Mar 15; 39(4):332-42. PubMed ID: 11169784
    [Abstract] [Full Text] [Related]

  • 27. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
    Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF.
    Ann Neurol; 1993 Sep 15; 34(3):423-31. PubMed ID: 8363363
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC, Lin KJ, Hsiao IT, Hsieh CJ, Lin WY, Lu CS, Wey SP, Yen TC, Kung MP, Weng YH.
    J Nucl Med; 2014 Jan 15; 55(1):73-9. PubMed ID: 24287322
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT.
    Votaw JR, Howell LL, Martarello L, Hoffman JM, Kilts CD, Lindsey KP, Goodman MM.
    Synapse; 2002 Jun 15; 44(4):203-10. PubMed ID: 11984856
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling Part I: PET studies.
    Saba W, Peyronneau MA, Dollé F, Goutal S, Bottlaender M, Valette H.
    Nucl Med Biol; 2012 Feb 15; 39(2):227-33. PubMed ID: 22033025
    [Abstract] [Full Text] [Related]

  • 39. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
    Honer M, Hengerer B, Blagoev M, Hintermann S, Waldmeier P, Schubiger PA, Ametamey SM.
    Nucl Med Biol; 2006 Jul 15; 33(5):607-14. PubMed ID: 16843835
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.